Richard Eastell

List of Publications by Year
in descending order

395 papers	43,306 citations	1883 102 h-index	2439 197 g-index
407 all docs	407 docs citations	407 times ranked	25682 citing authors

#	Article	IF	Citations
1	Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2009, 361, 756-765.	13.9	2,747
2	Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine, 2007, 356, 1809-1822.	13.9	2,536
3	Effect of Risedronate on the Risk of Hip Fracture in Elderly Women. New England Journal of Medicine, 2001, 344, 333-340.	13.9	1,831
4	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3561-3569.	1.8	1,277
5	Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nature Genetics, 2012, 44, 491-501.	9.4	1,100
6	Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. Journal of Bone and Mineral Research, 2015, 30, 3-23.	3.1	957
7	Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial. Lancet, The, 2009, 373, 1016-1024.	6.3	739
8	Relative contributions of testosterone and estrogen in regulating bone resorption and formation in normal elderly men. Journal of Clinical Investigation, 2000, 106, 1553-1560.	3.9	655
9	Treatment of Postmenopausal Osteoporosis. New England Journal of Medicine, 1998, 338, 736-746.	13.9	589
10	The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research, 2012, 27, 243-254.	3.1	552
11	Milk intake and bone mineral acquisition in adolescent girls: randomised, controlled intervention trial. BMJ: British Medical Journal, 1997, 315, 1255-1260.	2.4	547
12	Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate. Journal of Bone and Mineral Research, 2003, 18, 1051-1056.	3.1	535
13	Classification of vertebral fractures. Journal of Bone and Mineral Research, 1991, 6, 207-215.	3.1	525
14	Efficacy of Raloxifene on Vertebral Fracture Risk Reduction in Postmenopausal Women with Osteoporosis: Four-Year Results from a Randomized Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3609-3617.	1.8	490
15	Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1802-1822.	1.8	480
16	Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension. Journal of Bone and Mineral Research, 2018, 33, 190-198.	3.1	474
17	Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1595-1622.	1.8	470
18	Postmenopausal osteoporosis. Nature Reviews Disease Primers, 2016, 2, 16069.	18.1	462

#	Article	IF	Citations
19	Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. New England Journal of Medicine, 2010, 362, 1761-1771.	13.9	456
20	Underdiagnosis of Vertebral Fractures Is a Worldwide Problem: The IMPACT Study. Journal of Bone and Mineral Research, 2004, 20, 557-563.	3.1	440
21	Effects of teriparatide versus alendronate for treating glucocorticoidâ€induced osteoporosis: Thirtyâ€sixâ€“month results of a randomized, doubleâ€blind, controlled trial. Arthritis and Rheumatism, 2009, 60, 3346-3355.	6.7	406
22	The Effects of Tibolone in Older Postmenopausal Women. New England Journal of Medicine, 2008, 359, 697-708.	13.9	387
23	Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS. Bone, 2017, 105, 11-17.	1.4	373
24	Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. Journal of Clinical Oncology, 2008, 26, 1051-1057.	0.8	363
25	Lasofoxifene in Postmenopausal Women with Osteoporosis. New England Journal of Medicine, 2010, 362, 686-696.	13.9	342
26	Use of bone turnover markers in postmenopausal osteoporosis. Lancet Diabetes and Endocrinology,the, 2017, 5, 908-923.	5.5	336
27	Cancellous bone remodeling in type i (postmenopausal) osteoporosis: Quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. Journal of Bone and Mineral Research, 1990, 5, 311-319.	3.1	322
28	Subtrochanteric and Diaphyseal Femur Fractures in Patients Treated With Alendronate: A Register-Based National Cohort Study. Journal of Bone and Mineral Research, 2009, 24, 1095-1102.	3.1	316
29	The Impact of Monitoring on Adherence and Persistence with Antiresorptive Treatment for Postmenopausal Osteoporosis: A Randomized Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1117-1123.	1.8	311
30	Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Fourth International Workshop. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3570-3579.	1.8	296
31	Rates of vertebral bone loss before and after liver transplantation in women with primary biliary cirrhosis. Hepatology, 1991, 14, 296-300.	3.6	293
32	A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. Journal of Internal Medicine, 1998, 244, 271-292.	2.7	287
33	Effect of an Aromatase Inhibitor on BMD and Bone Turnover Markers: 2-Year Results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) Trial (18233230). Journal of Bone and Mineral Research, 2006, 21, 1215-1223.	3.1	285
34	Intrauterine Programming of Adult Body Composition¹. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 267-272.	1.8	275
35	International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine Position on bone marker standards in osteoporosis. Clinical Chemistry and Laboratory Medicine, 2011, 49, 1271-1274.	1.4	274
36	Diagnosis of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 340-350.	1.8	270

#	Article	IF	Citations
37	Bone Formation Rate in Older Normal Women: Concurrent Assessment with Bone Histomorphometry, Calcium Kinetics, and Biochemical Markers*. Journal of Clinical Endocrinology and Metabolism, 1988, 67, 741-748.	1.8	268
38	Differential Effects of Androgens and Estrogens on Bone Turnover in Normal Men. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 204-210.	1.8	265
39	Subclinical Thyroid Dysfunction and Fracture Risk. JAMA - Journal of the American Medical Association, 2015, 313, 2055.	3.8	264
40	Comparison of methods for the visual identification of prevalent vertebral fracture in osteoporosis. Osteoporosis International, 2004, 15, 887-896.	1.3	256
41	Association of Five Quantitative Ultrasound Devices and Bone Densitometry With Osteoporotic Vertebral Fractures in a Population-Based Sample: The OPUS Study. Journal of Bone and Mineral Research, 2004, 19, 782-793.	3.1	240
42	WNT16 Influences Bone Mineral Density, Cortical Bone Thickness, Bone Strength, and Osteoporotic Fracture Risk. PLoS Genetics, 2012, 8, e1002745.	1.5	240
43	Response of Biochemical Markers of Bone Turnover to Hormone Replacement Therapy: Impact of Biological Variability. Journal of Bone and Mineral Research, 1998, 13, 1124-1133.	3.1	235
44	Genome-Wide Association Study Using Extreme Truncate Selection Identifies Novel Genes Affecting Bone Mineral Density and Fracture Risk. PLoS Genetics, 2011, 7, e1001372.	1.5	233
45	Measurement of Osteocalcin. Annals of Clinical Biochemistry, 2000, 37, 432-446.	0.8	216
46	Relationship Between Changes in Bone Mineral Density and Vertebral Fracture Risk Associated With Risedronate. Journal of Clinical Densitometry, 2004, 7, 255-261.	0.5	211
47	Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treatment Reviews, 2008, 34, S3-S18.	3.4	209
48	Bone turnover markers: use in osteoporosis. Nature Reviews Rheumatology, 2012, 8, 379-389.	3.5	207
49	Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study. Journal of Bone and Mineral Research, 2005, 20, 1514-1524.	3.1	206
50	The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research, 2015, 30, 934-944.	3.1	205
51	Circulating Osteoprotegerin and Receptor Activator for Nuclear Factor Î¹B Ligand: Clinical Utility in Metabolic Bone Disease Assessment. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 6323-6331.	1.8	204
52	Prevention of Aromatase Inhibitorâ€“Induced Bone Loss Using Risedronate: The SABRE Trial. Journal of Clinical Oncology, 2010, 28, 967-975.	0.8	202
53	Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. New England Journal of Medicine, 2020, 383, 743-753.	13.9	201
54	Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. Journal of Bone and Mineral Research, 2019, 34, 632-642.	3.1	197

#	Article	IF	Citations
55	Bone Density, Microstructure and Strength in Obese and Normal Weight Men and Women in Younger and Older Adulthood. Journal of Bone and Mineral Research, 2015, 30, 920-928.	3.1	196
56	Effects of denosumab on bone turnover markers in postmenopausal osteoporosis. Journal of Bone and Mineral Research, 2011, 26, 530-537.	3.1	188
57	Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 393-402.	5.5	188
58	Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncology, The, 2008, 9, 866-872.	5.1	186
59	Case-Based Review of Osteonecrosis of the Jaw (ONJ) and Application of the International Recommendations for Management From the International Task Force on ONJ. Journal of Clinical Densitometry, 2017, 20, 8-24.	0.5	185
60	Interrelationship among vitamin D metabolism, true calcium absorption, parathyroid function, and age in women: Evidence of an age-related intestinal resistance to 1,25-dihydroxyvitamin D action. Journal of Bone and Mineral Research, 1991, 6, 125-132.	3.1	182
61	Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial. Journal of Bone and Mineral Research, 2011, 26, 1627-1637.	3.1	182
62	Glucocorticoid replacement therapy: are patients over treated and does it matter?. Clinical Endocrinology, 1997, 46, 255-261.	1.2	181
63	Identification of vertebral fractures: An update. Osteoporosis International, 2005, 16, 717-728.	1.3	174
64	Effect of Monitoring Bone Turnover Markers on Persistence with Risedronate Treatment of Postmenopausal Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 1296-1304.	1.8	173
65	Efficacy of risedronate on clinical vertebral fractures within six months. Current Medical Research and Opinion, 2004, 20, 433-439.	0.9	171
66	Safety and Efficacy of Risedronate in Reducing Fracture Risk in Osteoporotic Women Aged 80 and Older: Implications for the Use of Antiresorptive Agents in the Old and Oldest Old. Journal of the American Geriatrics Society, 2004, 52, 1832-1839.	1.3	167
67	A single nucleotide polymorphism (SNP) in the leptin receptor is associated with BMI, fat mass and leptin levels in postmenopausal Caucasian women. Human Genetics, 2001, 108, 233-236.	1.8	165
68	Biomarkers of bone health and osteoporosis risk. Proceedings of the Nutrition Society, 2008, 67, 157-162.	0.4	165
69	Attainment of peak bone mass at the lumbar spine, femoral neck and radius in men and women: relative contributions of bone size and volumetric bone mineral density. Osteoporosis International, 2004, 15, 263-273.	1.3	162
70	Thyroid Function within the Upper Normal Range Is Associated with Reduced Bone Mineral Density and an Increased Risk of Nonvertebral Fractures in Healthy Euthyroid Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3173-3181.	1.8	160
71	Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. Journal of Bone and Mineral Research, 2012, 27, 687-693.	3.1	156
72	Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS). Journal of Bone and Mineral Research, 2009, 24, 726-736.	3.1	149

#	Article	IF	Citations
73	Rapid and robust response of biochemical markers of bone formation to teriparatide therapy. Bone, 2009, 45, 1053-1058.	1.4	149
74	Cumulative Alendronate Dose and the Long-Term Absolute Risk of Subtrochanteric and Diaphyseal Femur Fractures: A Register-Based National Cohort Analysis. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 5258-5265.	1.8	147
75	A Longitudinal Study of Bone Gain in Pubertal Girls: Anthropometric and Biochemical Correlates. Journal of Bone and Mineral Research, 2009, 13, 1602-1612.	3.1	144
76	Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States. Journal of Bone and Mineral Research, 2009, 24, 389-397.	3.1	143
77	Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women. Journal of the National Cancer Institute, 2010, 102, 1706-1715.	3.0	138
78	Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone, 2004, 34, 187-194.	1.4	134
79	Circadian Variation in Ionized Calcium and Intact Parathyroid Hormone: Evidence for Sex Differences in Calcium Homeostasis*. Journal of Clinical Endocrinology and Metabolism, 1991, 72, 69-76.	1.8	132
80	Fracture Risk and Management of Discontinuation of Denosumab Therapy: A Systematic Review and Position Statement by ECTS. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 264-281.	1.8	132
81	Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. Osteoporosis International, 2000, 11, 331-337.	1.3	130
82	Multistage genome-wide association meta-analyses identified two new loci for bone mineral density. Human Molecular Genetics, 2014, 23, 1923-1933.	1.4	130
83	Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. Journal of Bone and Mineral Research, 2017, 32, 3-10.	3.1	127
84	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 2916-2946.	0.8	127
85	Role of oestrogen in the regulation of bone turnover at the menarche. Journal of Endocrinology, 2005, 185, 223-234.	1.2	126
86	Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. Journal of Bone and Mineral Research, 2012, 27, 211-218.	3.1	124
87	Bone fragility in diabetes: novel concepts and clinical implications. Lancet Diabetes and Endocrinology,the, 2022, 10, 207-220.	5.5	123
88	Biochemical Markers of Bone Turnover, Hip Bone Loss, and Fracture in Older Men: The MrOS Study. Journal of Bone and Mineral Research, 2009, 24, 2032-2038.	3.1	121
89	Efficacy and Safety of a Onceâ€Yearly Intravenous Zoledronic Acid 5â€ƒmg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older. Journal of the American Geriatrics Society, 2010, 58, 292-299.	1.3	121
90	Added value of trabecular bone score to bone mineral density for prediction of osteoporotic fractures in postmenopausal women: The OPUS study. Bone, 2013, 57, 232-236.	1.4	120

#	Article	IF	Citations
91	Cortical-Bone Fragility â€" Insights from sFRP4 Deficiency in Pyleâ€™s Disease. New England Journal of Medicine, 2016, 374, 2553-2562.	13.9	119
92	Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treatment Reviews, 1996, 22, 289-331.	3.4	118
93	The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: A systematic review and meta-analysis update. Bone, 2020, 137, 115457.	1.4	118
94	Management of corticosteroidâ€induced osteoporosis. Journal of Internal Medicine, 1995, 237, 439-447.	2.7	117
95	Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. Lancet Diabetes and Endocrinology,the, 2020, 8, 672-682.	5.5	117
96	Bisphosphonates for postmenopausal osteoporosis. Bone, 2011, 49, 82-88.	1.4	115
97	Changes in bone mass and bone turnover following tibial shaft fracture. Osteoporosis International, 2006, 17, 364-372.	1.3	114
98	Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: The OCEAN study. Journal of Bone and Mineral Research, 2011, 26, 1303-1312.	3.1	113
99	Development of an algorithm for using PINP to monitor treatment of patients with teriparatide. Current Medical Research and Opinion, 2006, 22, 61-66.	0.9	110
100	Free 25-hydroxyvitamin D is low in obesity, but there are no adverse associations with bone health. American Journal of Clinical Nutrition, 2016, 103, 1465-1471.	2.2	110
101	Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research, 2012, 27, 1627-1634.	3.1	109
102	Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4546-4554.	1.8	109
103	Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis. Journal of Bone and Mineral Research, 2009, 24, 1544-1551.	3.1	108
104	Increase in Vertebral Fracture Risk in Postmenopausal Women Using Omeprazole. Calcified Tissue International, 2009, 84, 13-19.	1.5	107
105	Risk of fractures in patients with pernicious anemia. Journal of Bone and Mineral Research, 1992, 7, 573-579.	3.1	107
106	Bone Disease after Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1282-1296.	2.2	106
107	Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion: effects of growth and ageing. Clinical Science, 1992, 83, 375-382.	1.8	104
108	Octreotide Abolishes the Acute Decrease in Bone Turnover in Response to Oral Glucose. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 4867-4873.	1.8	103

#	Article	IF	Citations
109	Femoral and Vertebral Strength Improvements in Postmenopausal Women With Osteoporosis Treated With Denosumab. Journal of Bone and Mineral Research, 2014, 29, 158-165.	3.1	98
110	Prevention and management of osteoporosis. Medicine, 2017, 45, 565-569.	0.2	97
111	DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?. European Journal of Endocrinology, 2018, 178, R19-R31.	1.9	97
112	Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 3215-3225.	1.8	96
113	Effect of Pamidronate in Preventing Local Bone Loss After Total Hip Arthroplasty: A Randomized, Double-Blind, Controlled Trial. Journal of Bone and Mineral Research, 2001, 16, 556-564.	3.1	93
114	Effects of the Src kinase inhibitor saracatinib (AZD0530) on bone turnover in healthy men: A randomized, double-blind, placebo-controlled, multiple-ascending-dose phase I trial. Journal of Bone and Mineral Research, 2010, 25, 463-471.	3.1	92
115	Rosiglitazone Decreases Bone Mineral Density and Increases Bone Turnover in Postmenopausal Women With Type 2 Diabetes Mellitus. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1519-1528.	1.8	92
116	Bone Turnover and Bone Mineral Density Are Independently Related to Selenium Status in Healthy Euthyroid Postmenopausal Women. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 4061-4070.	1.8	91
117	Renal safety in patients treated with bisphosphonates for osteoporosis: A review. Journal of Bone and Mineral Research, 2013, 28, 2049-2059.	3.1	91
118	Genetic determinants of heel bone properties: genome-wide association meta-analysis and replication in the GEFOS/GENOMOS consortium. Human Molecular Genetics, 2014, 23, 3054-3068.	1.4	90
119	Bone mineral density and biochemical markers of bone turnover in aseptic loosening after total hip arthroplasty. Journal of Orthopaedic Research, 2003, 21, 691-696.	1.2	89
120	11Î²-Hydroxysteroid Dehydrogenase Type 1 Activity Predicts the Effects of Glucocorticoids on Bone. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 3874-3877.	1.8	89
121	Effects of third generation aromatase inhibitors on bone health and other safety parameters: Results of an open, randomised, multi-centre study of letrozole, exemestane and anastrozole in healthy postmenopausal women. European Journal of Cancer, 2007, 43, 2523-2531.	1.3	85
122	The Efficacy and Safety of Vertebral Augmentation: A Second ASBMR Task Force Report. Journal of Bone and Mineral Research, 2019, 34, 3-21.	3.1	83
123	Polyethylene wear rate and osteolysis: Critical threshold versus continuous dose-response relationship. Journal of Orthopaedic Research, 2005, 23, 520-525.	1.2	82
124	Diagnostic Accuracy of Biomarkers and Imaging for Bone Turnover in Renal Osteodystrophy. Journal of the American Society of Nephrology: JASN, 2018, 29, 1557-1565.	3.0	82
125	Potential Role of Pancreatic and Enteric Hormones in Regulating Bone Turnover. Journal of Bone and Mineral Research, 2005, 20, 1497-1506.	3.1	79
126	More on Reports of Esophageal Cancer with Oral Bisphosphonate Use. New England Journal of Medicine, 2009, 360, 1789-1792.	13.9	79

#	Article	IF	Citations
127	Use of DXA-based finite element analysis of the proximal femur in a longitudinal study of hip fracture. Journal of Bone and Mineral Research, 2013, 28, 1014-1021.	3.1	78
128	Treatment of Isolated Hypogonadotropic Hypogonadism Effect on Bone Mineral Density and Bone Turnover. Journal of Clinical Endocrinology and Metabolism, 1997, 82, 658-665.	1.8	76
129	Bone Mass and Muscle Strength in Female College Athletes (Runners and Swimmers). Mayo Clinic Proceedings, 1998, 73, 1151-1160.	1.4	76
130	Long-term effects of anastrozole on bone mineral density: 7-year results from the ATAC trial. Annals of Oncology, 2011, 22, 857-862.	0.6	76
131	Proton Pump Inhibitor Use and the Antifracture Efficacy of Alendronate. Archives of Internal Medicine, 2011, 171, 998-1004.	4.3	76
132	Acute Changes of Bone Turnover and PTH Induced by Insulin and Glucose: Euglycemic and Hypoglycemic Hyperinsulinemic Clamp Studies. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 3324-3329.	1.8	75
133	One-day test using stable isotopes to measure true fractional calcium absorption. Journal of Bone and Mineral Research, 1989, 4, 463-468.	3.1	75
134	Effect of Stopping Risedronate after Long-Term Treatment on Bone Turnover. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 3367-3373.	1.8	75
135	Determination of Free 25(OH)D Concentrations and Their Relationships to Total 25(OH)D in Multiple Clinical Populations. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 3278-3288.	1.8	74
136	Monitoring Alendronate Therapy for Osteoporosis. Journal of Bone and Mineral Research, 1999, 14, 602-608.	3.1	73
137	Bone turnover markers and bone mineral density response with risedronate therapy: Relationship with fracture risk and patient adherence. Journal of Bone and Mineral Research, 2011, 26, 1662-1669.	3.1	73
138	Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. BMJ, The, 2016, 353, i3365.	3.0	73
139	Variation in the TNF Gene Promoter and Risk of Osteolysis After Total Hip Arthroplasty. Journal of Bone and Mineral Research, 2003, 18, 1995-2001.	3.1	72
140	Relationship of Early Changes in Bone Resorption to the Reduction in Fracture Risk With Risedronate: Review of Statistical Analysis. Journal of Bone and Mineral Research, 2007, 22, 1656-1660.	3.1	72
141	Proportion of human vertebral body bone that is cancellous. Journal of Bone and Mineral Research, 1990, 5, 1237-1241.	3.1	72
142	Reference intervals of bone turnover markers in healthy premenopausal women: Results from a cross-sectional European study. Bone, 2012, 50, 1141-1147.	1.4	71
143	Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine. Clinical Endocrinology, 1997, 46, 301-307.	1.2	69
144	Absence of Marked Seasonal Change in Bone Turnover: A Longitudinal and Multicenter Cross-Sectional Study. Journal of Bone and Mineral Research, 2003, 18, 1274-1281.	3.1	69

#	Article	IF	Citations
145	A Comparison of the Effects of Raloxifene and Conjugated Equine Estrogen on Bone and Lipids in Healthy Postmenopausal Women. Archives of Internal Medicine, 2004, 164, 871.	4.3	68
146	Differential effects of teriparatide on regional bone formation using 18F-fluoride positron emission tomography. Journal of Bone and Mineral Research, 2011, 26, 1002-1011.	3.1	68
147	Colles' fracture and bone density of the ultradistal radius. Journal of Bone and Mineral Research, 1989, 4, 607-613.	3.1	67
148	Levels of serotonin, sclerostin, bone turnover markers as well as bone density and microarchitecture in patients with high-bone-mass phenotype due to a mutation in Lrp5. Journal of Bone and Mineral Research, 2011, 26, 1721-1728.	3.1	67
149	Polymorphisms in the interleukinâ€1 receptor antagonist and interleukinâ€6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis and Rheumatism, 2008, 58, 3157-3165.	6.7	66
150	Effect of Nitroglycerin Ointment on Bone Density and Strength in Postmenopausal Women. JAMA - Journal of the American Medical Association, 2011, 305, 800.	3.8	66
151	Association Between Drug Treatments for Patients With Osteoporosis and Overall Mortality Rates. JAMA Internal Medicine, 2019, 179, 1491.	2.6	66
152	Mechanisms of bone loss after cardiac transplantation. Bone, 1998, 22, 267-271.	1.4	65
153	Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: A randomized trial. Journal of Orthopaedic Research, 2005, 23, 1-8.	1.2	64
154	Effect of ONO-5334 on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Osteoporosis: 2-Year Results From the OCEAN Study. Journal of Bone and Mineral Research, 2014, 29, 458-466.	3.1	64
155	Diet and Healthy Bones. Calcified Tissue International, 2002, 70, 400-404.	1.5	63
156	Identification of Vertebral Fracture and Non-Osteoporotic Short Vertebral Height in Men: The MrOS Study. Journal of Bone and Mineral Research, 2007, 22, 1434-1441.	3.1	63
157	Prediction of Incident Hip Fracture with the Estimated Femoral Strength by Finite Element Analysis of DXA Scans in the Study of Osteoporotic Fractures. Journal of Bone and Mineral Research, 2014, 29, 2594-2600.	3.1	63
158	Algorithm-Based Qualitative and Semiquantitative Identification of Prevalent Vertebral Fracture: Agreement Between Different Readers, Imaging Modalities, and Diagnostic Approaches. Journal of Bone and Mineral Research, 2008, 23, 417-424.	3.1	62
159	Use of DXA-Based Structural Engineering Models of the Proximal Femur to Discriminate Hip Fracture. Journal of Bone and Mineral Research, 2009, 24, 33-42.	3.1	61
160	The effect of a fortified milk drink on vitamin D status and bone turnover in post-menopausal women from South East Asia. Bone, 2010, 46, 759-767.	1.4	61
161	Long-term effects of aromatase inhibitors on bone. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 151-154.	1.2	60
162	Effects of Estrogen Therapy of Postmenopausal Women on Cytokines Measured in Peripheral Blood. Journal of Bone and Mineral Research, 2009, 13, 1577-1586.	3.1	60

#	Article	IF	Citations
163	Distribution of bone density and cortical thickness in the proximal femur and their association with hip fracture in postmenopausal women: a quantitative computed tomography study. Osteoporosis International, 2014, 25, 251-263.	1.3	60
164	Secondary prevention of osteoporosis: when should a non-vertebral fracture be a trigger for action?. QJM - Monthly Journal of the Association of Physicians, 2001, 94, 575-597.	0.2	59
165	Calcium supplementation and bone mineral accretion in adolescent girls: an 18-mo randomized controlled trial with 2-y follow-up. American Journal of Clinical Nutrition, 2008, 87, 455-462.	2.2	58
166	Osteoporosis in men. Lancet Diabetes and Endocrinology,the, 2022, 10, 273-283.	5.5	58
167	Esophageal and gastric cancer incidence and mortality in alendronate users. Journal of Bone and Mineral Research, 2012, 27, 679-686.	3.1	57
168	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncology, The, 2014, 15, 1460-1468.	5.1	56
169	Pernicious anaemia as a risk factor for osteoporosis. Clinical Science, 1992, 82, 681-685.	1.8	55
170	Risk Factors for Vertebral and Nonvertebral Fracture Over 10 Years: A Population-Based Study in Women. Journal of Bone and Mineral Research, 2008, 23, 75-85.	3.1	55
171	A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. Journal of Bone and Mineral Research, 2010, 25, 32-40.	3.1	55
172	Goal-directed treatment of osteoporosis. Journal of Bone and Mineral Research, 2013, 28, 433-438.	3.1	54
173	Serum microRNAs as novel biomarkers for osteoporotic vertebral fractures. Bone, 2020, 130, 115105.	1.4	54
174	Glucocorticoid-induced osteoporosis. Current Opinion in Rheumatology, 2001, 13, 326-332.	2.0	53
175	Medical Management of Patients After Atypical Femur Fractures: a Systematic Review and Recommendations From the European Calcified Tissue Society. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1682-1699.	1.8	53
176	Recent studies of human calcium metabolism using stable isotopic tracers. Canadian Journal of Physiology and Pharmacology, 1990, 68, 973-976.	0.7	52
177	Diclofenac sodium inhibits bone resorption in postmenopausal women. American Journal of Medicine, 1994, 96, 349-353.	0.6	51
178	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. Journal of Bone and Mineral Research, 2018, 33, 634-642.	3.1	51
179	Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e1171-e1186.	1.8	51
180	Vitamin D status in professional ballet dancers: Winter vs. summer. Journal of Science and Medicine in Sport, 2013, 16, 388-391.	0.6	50

#	Article	IF	Citations
181	BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. Journal of Bone and Mineral Research, 2013, 28, 1319-1327.	3.1	50
182	Measurement of Osteocalcin. , 0, .		50
183	Assessment and Recommendations on Factors Contributing to Preanalytical Variability of Urinary Pyridinoline and Deoxypyridinoline. Clinical Chemistry, 2002, 48, 220-235.	1.5	49
184	Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 767-775.	5.5	48
185	The Performance and Utility of Biochemical Markers of Bone Turnover: Do We Know Enough to Use Them in Clinical Practice?. Annals of Clinical Biochemistry, 1997, 34, 449-459.	0.8	47
186	Effects of Depot Medroxyprogesterone Acetate on Bone Density and Bone Metabolism before and after Peak Bone Mass: A Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 1317-1323.	1.8	47
187	Distribution of bone density in the proximal femur and its association with hip fracture risk in older men: The osteoporotic fractures in men (MrOS) study. Journal of Bone and Mineral Research, 2012, 27, 2314-2324.	3.1	47
188	Device-specific thresholds to diagnose osteoporosis at the proximal femur: an approach to interpreting peripheral bone measurements in clinical practice. Osteoporosis International, 2006, 17, 1293-1302.	1.3	46
189	Bone Turnover Markers: Use in Fracture Prediction. Journal of Clinical Densitometry, 2017, 20, 346-352.	0.5	46
190	Mifepristone Reduces Insulin Resistance in Patient Volunteers with Adrenal Incidentalomas That Secrete Low Levels of Cortisol: A Pilot Study. PLoS ONE, 2013, 8, e60984.	1.1	45
191	FRAXÂ®: Prediction of Major Osteoporotic Fractures in Women from the General Population: The OPUS Study. PLoS ONE, 2013, 8, e83436.	1.1	45
192	Biochemical markers of bone turnover and development of heterotopic ossification after total hip arthroplasty. Journal of Orthopaedic Research, 2003, 21, 529-534.	1.2	44
193	Health-related quality of life and a cost-utility simulation of adults in the UK with osteogenesis imperfecta, X-linked hypophosphatemia and fibrous dysplasia. Orphanet Journal of Rare Diseases, 2016, 11, 160.	1.2	44
194	Six Months of Parathyroid Hormone (1â€“84) Administered ConcurrentlyVersusSequentially with Monthly Ibandronate Over Two Years: The PTH and Ibandronate Combination Study (PICS) Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3522-3529.	1.8	43
195	Fragility Fractures and Osteoporosis in CKD: Pathophysiology and Diagnostic Methods. American Journal of Kidney Diseases, 2014, 63, 1049-1059.	2.1	43
196	The discriminative ability of peripheral and axial bone measurements to identify proximal femoral, vertebral, distal forearm and proximal humeral fractures: a case control study. Osteoporosis International, 2005, 16, 1794-1802.	1.3	42
197	Comparison of Densitometric and Radiographic Vertebral Fracture Assessment Using the Algorithm-Based Qualitative (ABQ) Method in Postmenopausal Women at Low and High Risk of Fracture. Journal of Bone and Mineral Research, 2008, 23, 103-111.	3.1	42
198	Precision of High-Resolution Peripheral Quantitative Computed Tomography Measurement Variables: Influence of Gender, Examination Site, and Age. Calcified Tissue International, 2014, 94, 191-201.	1.5	42

#	Article	IF	Citations
199	A randomised, double-blinded, placebo-controlled, trial to determine the individual response in bone turnover markers to lasofoxifene therapy. Bone, 2009, 45, 1044-1052.	1.4	41
200	Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis. Circulation, 2010, 122, 1716-1724.	1.6	41
201	Thyroid Function Tests in the Reference Range and Fracture: Individual Participant Analysis of Prospective Cohorts. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2719-2728.	1.8	41
202	Denosumab in postmenopausal women with osteoporosis and diabetes: Subgroup analysis of FREEDOM and FREEDOM extension. Bone, 2020, 134, 115268.	1.4	41
203	Plenary Lecture: Strategies for skeletal health in the elderly. Proceedings of the Nutrition Society, 2002, 61, 173-180.	0.4	40
204	Effect of once-yearly zoledronic acid on the spine and hip as measured by quantitative computed tomography: results of the HORIZON Pivotal Fracture Trial. Osteoporosis International, 2010, 21, 1277-1285.	1.3	40
205	Effects of antiresorptive treatment on nonvertebral fracture outcomes. Journal of Bone and Mineral Research, 2011, 26, 2411-2418.	3.1	40
206	Osteoporosis in men. Nature Reviews Endocrinology, 2013, 9, 637-645.	4.3	39
207	Determinants of the Maternal 25-Hydroxyvitamin D Response to Vitamin D Supplementation During Pregnancy. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 5012-5020.	1.8	38
208	Bone turnover markers after the menopause: T-score approach. Bone, 2018, 111, 44-48.	1.4	38
209	Individual susceptibility to periprosthetic osteolysis is associated with altered patterns of innate immune gene expression in response to proâ€inflammatory stimuli. Journal of Orthopaedic Research, 2010, 28, 1127-1135.	1.2	37
210	Evaluation of serum concentrations of biochemical markers of bone metabolism and insulin-like growth factor I associated with treadmill exercise in young horses. American Journal of Veterinary Research, 2003, 64, 1549-1556.	0.3	36
211	The Effect of the Cathepsin K Inhibitor ONO-5334 on Trabecular and Cortical Bone in Postmenopausal Osteoporosis: The OCEAN Study. Journal of Bone and Mineral Research, 2014, 29, 629-638.	3.1	36
212	Variation in the secreted frizzled-related protein-3 gene and risk of Osteolysis and heterotopic ossification after total hip arthroplasty. Journal of Orthopaedic Research, 2007, 25, 1665-1670.	1.2	35
213	Oxytocin, a New Determinant of Bone Mineral Density in Post-Menopausal Women: Analysis of the OPUS Cohort. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E634-E641.	1.8	35
214	Pain, Quality of Life, and Safety Outcomes of Kyphoplasty for Vertebral Compression Fractures: Report of a Task Force of the American Society for Bone and Mineral Research. Journal of Bone and Mineral Research, 2017, 32, 1935-1944.	3.1	35
215	Bone Turnover in Preterm Infants. Pediatric Research, 1999, 45, 363-366.	1.1	35
216	Treatment of Isolated Hypogonadotropic Hypogonadism Effect on Bone Mineral Density and Bone Turnover. , 0, .		35

#	Article	IF	Citations
217	Diagnostic Evaluation of Osteoporosis. Endocrinology and Metabolism Clinics of North America, 1988, 17, 547-571.	1.2	34
218	Anabolic treatment for osteoporosis: teriparatide. Clinical Cases in Mineral and Bone Metabolism, 2017, 14, 173.	1.0	33
219	Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice. Osteoporosis International, 2013, 24, 941-947.	1.3	32
220	Effect of age and gender on serum periostin: Relationship to cortical measures, bone turnover and hormones. Bone, 2017, 99, 8-13.	1.4	32
221	Biochemical markers of bone turnover and fracture prediction. The Journal of the British Menopause Society, 2003, 9, 10-15.	1.3	32
222	Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate. Bone, 2010, 46, 929-934.	1.4	31
223	Dietary Phosphate Modulates Atherogenesis and Insulin Resistance in Apolipoprotein E Knockout Miceâ€"Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 1988-1990.	1.1	31
224	Analytical considerations and plans to standardize or harmonize assays for the reference bone turnover markers PINP and Î²-CTX in blood. Clinica Chimica Acta, 2021, 515, 16-20.	0.5	31
225	Bone markers and current laboratory assays. Cancer Treatment Reviews, 2006, 32, 7-14.	3.4	30
226	Cardiovascular disease and bone. Archives of Biochemistry and Biophysics, 2010, 503, 78-83.	1.4	30
227	Serum Galactosyl Hydroxylysine as a Biochemical Marker of Bone Resorption. Clinical Chemistry, 1999, 45, 676-681.	1.5	29
228	Management of osteoporosis due to ovarian failure. Medical and Pediatric Oncology, 2003, 41, 222-227.	1.0	29
229	Monitoring Alendronate and Estradiol Therapy With Quantitative Ultrasound and Bone Mineral Density. Journal of Clinical Densitometry, 2005, 8, 278-286.	0.5	29
230	Cortical Consolidation of the Radius and Tibia in Young Men and Women. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3342-3348.	1.8	29
231	A Vitamin D, Calcium and Leucine-Enriched Whey Protein Nutritional Supplement Improves Measures of Bone Health in Sarcopenic Non-Malnourished Older Adults: The PROVIDE Study. Calcified Tissue International, 2019, 105, 383-391.	1.5	29
232	Risks of Hip and Nonvertebral Fractures in Patients With CKD G3a-G5D: A Systematic Review and Meta-analysis. American Journal of Kidney Diseases, 2020, 76, 521-532.	2.1	29
233	Biochemical markers of bone turnover. Current Opinion in Nephrology and Hypertension, 1999, 8, 421-427.	1.0	29
234	Stable Strontium Absorption as a Measure of Intestinal Calcium Absorption: Comparison with the Double-Radiotracer Calcium Absorption Test. Clinical Science, 1994, 87, 363-368.	1.8	28

#	Article	IF	Citations
235	Influence of bone quality on the strength of internal and external fixation of tibial plateau fractures. Journal of Orthopaedic Research, 2006, 24, 2080-2086.	1.2	28
236	The effect of cessation of raloxifene treatment on bone turnover in postmenopausal women. Bone, 2010, 46, 592-597.	1.4	28
237	Milk Supplementation and Bone Health in Young Adult Chinese Women. Journal of Women's Health, 2007, 16, 692-702.	1.5	26
238	The Initial Slope of the Variogram, Foundation of the Trabecular Bone Score, Is Not or Is Poorly Associated With Vertebral Strength. Journal of Bone and Mineral Research, 2016, 31, 341-346.	3.1	26
239	Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension. RMD Open, 2021, 7, e001714.	1.8	26
240	Developing a toolkit for the assessment and monitoring of musculoskeletal ageing. Age and Ageing, 2018, 47, iv1-iv19.	0.7	25
241	A multicenter study to evaluate harmonization of assays for N-terminal propeptide of type I procollagen (PINP): a report from the IFCC-IOF Joint Committee for Bone Metabolism. Clinical Chemistry and Laboratory Medicine, 2019, 57, 1546-1555.	1.4	25
242	Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study. Bone, 2012, 50, 885-892.	1.4	24
243	Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. Journal of Bone and Mineral Research, 2016, 31, 1767-1773.	3.1	24
244	Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes. Journal of Bone and Mineral Research, 2020, 35, 2363-2371.	3.1	24
245	Establishing reference intervals for bone turnover markers in healthy postmenopausal women in a nonfasting state. BoneKEy Reports, 2014, 3, 573.	2.7	23
246	Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. Journal of Bone and Mineral Research, 2020, 37, 29-35.	3.1	23
247	Hormonal determinants of bone turnover before and after attainment of peak bone mass. Clinical Endocrinology, 2010, 72, 320-327.	1.2	22
248	Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study. Osteoporosis International, 2013, 24, 321-328.	1.3	22
249	Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. Journal of Bone and Mineral Research, 2019, 34, 810-816.	3.1	22
250	Effect of selenium supplementation on musculoskeletal health in older women: a randomised, double-blind, placebo-controlled trial. The Lancet Healthy Longevity, 2021, 2, e212-e221.	2.0	22
251	Calcium Homeostasis and Osteoporosis. Endocrinology and Metabolism Clinics of North America, 1987, 16, 829-842.	1.2	21
252	Zinc supplementation and bone growth in pubertal girls. Lancet, The, 1999, 354, 485.	6.3	21

#	Article	IF	Citations
253	Accuracy and Precision of Peripheral Quantitative Computed Tomography Measurements at the Tibial Metaphysis. Journal of Clinical Densitometry, 2004, 7, 209-217.	0.5	21
254	Effects of calcium-fortified ice cream on markers of bone health. Osteoporosis International, 2011, 22, 2721-2731.	1.3	21
255	Statistical Shape and Appearance Models in Osteoporosis. Current Osteoporosis Reports, 2014, 12, 163-173.	1.5	21
256	Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study. Journal of Bone and Mineral Research, 2015, 30, 570-574.	3.1	21
257	Risk and Prevention of Fracture in Patients With Major Medical Illnesses: A Mini-Review. Journal of Bone and Mineral Research, 2016, 31, 2069-2072.	3.1	21
258	A Pooled Analysis of Fall Incidence From Placeboâ€€Controlled Trials of Denosumab. Journal of Bone and Mineral Research, 2020, 35, 1014-1021.	3.1	21
259	A Novel EXT1 Splice Site Mutation in a Kindred with Hereditary Multiple Exostosis and Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 5386-5392.	1.8	20
260	International variation in proximal femur bone mineral density. Osteoporosis International, 2011, 22, 721-729.	1.3	20
261	Aromatase inhibitors and bone. Journal of Steroid Biochemistry and Molecular Biology, 2007, 106, 157-161.	1.2	19
262	Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 1302-1309.	1.8	19
263	Efficacy of Zoledronic Acid in Maintaining Areal and Volumetric Bone Density After Combined Denosumab and Teriparatide Administration: DATA-HD Study Extension. Journal of Bone and Mineral Research, 2020, 36, 921-930.	3.1	19
264	Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports. Journal of Bone and Mineral Research, 2020, 37, 1188-1199.	3.1	19
265	Measurement of bone mass and turnover. Bailliere's Clinical Rheumatology, 1993, 7, 479-498.	1.0	18
266	Heart drugs that affect bone. Trends in Endocrinology and Metabolism, 2012, 23, 163-168.	3.1	18
267	Discordant pattern of peripheral fractures in diabetes: a meta-analysis on the risk of wrist and ankle fractures. Osteoporosis International, 2019, 30, 135-143.	1.3	18
268	Vascular calcification relationship to vascular biomarkers and bone metabolism in advanced chronic kidney disease. Bone, 2021, 143, 115699.	1.4	18
269	The Effects of Type 1 Diabetes and Diabetic Peripheral Neuropathy on the Musculoskeletal System: A Caseâ€“Control Study. Journal of Bone and Mineral Research, 2020, 36, 1048-1059.	3.1	18
270	The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Best Practice and Research in Clinical Endocrinology and Metabolism, 2000, 14, 213-232.	2.2	17

#	Article	IF	Citations
271	Effect of Temperature on the Longitudinal Variability of Quantitative Ultrasound Variables. Journal of Clinical Densitometry, 2005, 8, 436-444.	0.5	17
272	Circulating Serotonin and Bone Density, Structure, and Turnover in Carcinoid Syndrome. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 2902-2907.	1.8	17
273	Clinical and biochemical characteristics of adults with hypophosphatasia attending a metabolic bone clinic. Bone, 2021, 144, 115795.	1.4	17
274	Bisphosphonates and the risk of atypical femur fractures. Bone, 2022, 156, 116297.	1.4	17
275	Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. Osteoporosis International, 2013, 24, 329-338.	1.3	16
276	Incidence and Predictors of Multiple Fractures Despite High Adherence to Oral Bisphosphonates: A Binational Population-Based Cohort Study. Journal of Bone and Mineral Research, 2016, 31, 234-244.	3.1	16
277	The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone, 2020, 136, 115336.	1.4	16
278	The Nocturnal Increase in Growth Hormone Is not the Cause of the Nocturnal Increase in Serum Osteocalcin*. Journal of Clinical Endocrinology and Metabolism, 1991, 73, 368-372.	1.8	15
279	Vitamin D and Osteoporosis. , 2005, , 1101-1120.		15
280	Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. Obstetrical and Gynecological Survey, 2009, 64, 805-807.	0.2	15
281	Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. Journal of Bone and Mineral Research, 2012, 27, 1487-1493.	3.1	15
282	Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. Journal of Bone and Mineral Research, 2020, 36, 236-243.	3.1	15
283	Reference interval for albuminâ€adjusted calcium based on a large UK population. Clinical Endocrinology, 2021, 94, 34-39.	1.2	15
284	Normocalcaemic hypoparathyroidism: prevalence and effect on bone status in older women. The <scp>OPUS</scp> study. Clinical Endocrinology, 2015, 82, 816-823.	1.2	14
285	Antiresorptive effect of a cathepsin K inhibitor ONO-5334 and its relationship to BMD increase in a phase II trial for postmenopausal osteoporosis. BMC Musculoskeletal Disorders, 2017, 18, 267.	0.8	14
286	Standardised quantitative morphometry: a modified approach for quantitative identification of prevalent vertebral deformities. Osteoporosis International, 2007, 18, 1411-1419.	1.3	13
287	Effects of raloxifene and alendronate on bone turnover as assessed by procollagen type I N-terminal propeptide. Osteoporosis International, 2011, 22, 1927-1934.	1.3	13
288	Development and validation of a subject-specific finite element model of the functional spinal unit to predict vertebral strength. Proceedings of the Institution of Mechanical Engineers, Part H: Journal of Engineering in Medicine, 2017, 231, 821-830.	1.0	13

#	Article	IF	Citations
289	Effect of vitamin D supplementation on free and total vitamin D: A comparison of Asians and Caucasians. Clinical Endocrinology, 2019, 90, 222-231.	1.2	13
290	Real-world bone turnover marker use: impact on treatment decisions and fracture. Osteoporosis International, 2021, 32, 831-840.	1.3	13
291	The Renal Clearance of Free and Peptide-Bound Deoxypyridinoline: Response to Pamidronate Treatment of Paget's Disease. Journal of Bone and Mineral Research, 2003, 18, 658-661.	3.1	12
292	Adaptation of the Carter Method to Adjust Lumbar Spine Bone Mineral Content for Age and Body Size: Application to Children Who Were Born Preterm. Journal of Clinical Densitometry, 2006, 9, 114-119.	0.5	12
293	Association of incident hip fracture with the estimated femoral strength by finite element analysis of DXA scans in the Osteoporotic Fractures in Men (MrOS) study. Osteoporosis International, 2018, 29, 643-651.	1.3	12
294	Urinary calcium indices in primary hyperparathyroidism (PHPT) and familial hypocalciuric hypercalcaemia (FHH): which test performs best?. Postgraduate Medical Journal, 2021, 97, 577-582.	0.9	12
295	Shape, Structural Properties, and Cortical Stability Along the Femoral Neck: A Study Using Clinical QCT. Journal of Clinical Densitometry, 2008, 11, 373-382.	0.5	11
296	Degenerative inter-vertebral disc disease osteochondrosis intervertebralis in Europe: prevalence, geographic variation and radiological correlates in men and women aged 50 and over. Rheumatology, 2017, 56, 1189-1199.	0.9	11
297	Comparison of femoral strength and fracture risk index derived from DXA-based finite element analysis for stratifying hip fracture risk: A cross-sectional study. Bone, 2018, 110, 386-391.	1.4	11
298	Dietary Selenium Intakes and Musculoskeletal Function in Very Old Adults: Analysis of the Newcastle 85+ Study. Nutrients, 2020, 12, 2068.	1.7	11
299	Establishing race-, gender- and age-specific reference intervals for pyridoxal 5â€²-phosphate in the NHANES population to better identify adult hypophosphatasia. Bone, 2020, 141, 115577.	1.4	11
300	Management of Bone Health in Postmenopausal Women. Hormone Research in Paediatrics, 2005, 64, 76-80.	0.8	10
301	A Model of BMD Changes After Alendronate Discontinuation to Guide Postalendronate BMD Monitoring. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 4094-4100.	1.8	10
302	Raman Spectroscopic Analysis of Fingernail Clippings Can Help Differentiate between Postmenopausal Women who Have and Have Not Suffered a Fracture. Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders, 2016, 9, CMAMD.S38493.	0.3	10
303	The risk of hip and non-vertebral fractures in patients with Parkinson's disease and parkinsonism: A systematic review and meta-analysis. Bone, 2020, 132, 115173.	1.4	10
304	Pleiotropic associations of heterozygosity for the SERPINA1 Z allele in the UK Biobank. ERJ Open Research, 2021, 7, 00049-2021.	1.1	10
305	Bone turnover in pregnancy, measured by urinary CTX, is influenced by vitamin D supplementation and is associated with maternal bone health: findings from the Maternal Vitamin D Osteoporosis Study (MAVIDOS) trial. American Journal of Clinical Nutrition, 2021, 114, 1600-1611.	2.2	10
306	Pregnancy Vitamin D Supplementation and Childhood Bone Mass at Age 4â€‰Years: Findings From the Maternal Vitamin D Osteoporosis Study (MAVIDOS) Randomized Controlled Trial. JBMR Plus, 2022, 6, .	1.3	10

#	Article	IF	Citations
307	Comparison of polyethylene glycol and chromium-51 chloride as nonabsorbable stool markers in calcium balance studies. Bone and Mineral, 1989, 6, 95-105.	2.0	9
308	Optimization of glucocorticoid replacement therapy: the long-term effect on bone mineral density. Clinical Endocrinology, 1999, 50, 815-817.	1.2	9
309	How to Interpret Surrogate Markers of Efficacy in Osteoporosis. Journal of Bone and Mineral Research, 2005, 20, 1261-1262.	3.1	9
310	Tree-structured Subgroup Analysis of Receiver Operating Characteristic Curves for Diagnostic Tests. Academic Radiology, 2012, 19, 1529-1536.	1.3	9
311	THRA and DIO2 mutations are unlikely to be a common cause of increased bone mineral density in euthyroid post-menopausal women. European Journal of Endocrinology, 2014, 170, 637-644.	1.9	9
312	A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 2018, 118, 770-776.	2.9	9
313	Comparison of risedronate versus placebo in preventing anastrozole-induced bone loss in women at high risk of developing breast cancer with osteopenia. Bone, 2019, 124, 83-88.	1.4	9
314	Maternal pregnancy vitamin D supplementation increases offspring bone formation in response to mechanical loading: Findings from a MAVIDOS Trial sub-study. Journal of Musculoskeletal Neuronal Interactions, 2020, 20, 4-11.	0.1	9
315	Assessment and recommendations on factors contributing to preanalytical variability of urinary pyridinoline and deoxypyridinoline. Clinical Chemistry, 2002, 48, 220-35.	1.5	9
316	New Approaches to the Treatment of Osteoporosis. Clinical Obstetrics and Gynecology, 1987, 30, 860-870.	0.6	8
317	Markers of bone and collagen breakdown in early inflammatory arthritis. Bailliere's Clinical Rheumatology, 1992, 6, 351-372.	1.0	8
318	Bone Metabolism and Osteoporosis. The Journal of the British Menopause Society, 1998, 4, 103-106.	1.3	8
319	Optimal Thresholds, Linear or Nonlinear Relationships of Fracture Risk Reduction With Therapy. Journal of Bone and Mineral Research, 2008, 23, 1350-1350.	3.1	8
320	Depot medroxyprogesterone acetate use after peak bone mass is associated with increased bone turnover but no decrease in bone mineral density. Fertility and Sterility, 2010, 93, 697-701.	0.5	8
321	Lipid profiles within the SABRE trial of anastrozole with and without risedronate. Breast Cancer Research and Treatment, 2012, 134, 1141-1147.	1.1	8
322	Response to Letter to the Editor: â€œPharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guidelineâ€• Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3537-3538.	1.8	8
323	The role of static bone histomorphometry in diagnosing renal osteodystrophy. Bone, 2021, 142, 115689.	1.4	8
324	Breast Cancer and the Risk of Osteoporotic Fracture: A Paradox. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 42-43.	1.8	7

#	Article	IF	Citations
325	Biochemical Markers of Bone Turnover. , 2007, , 337-349.		7
326	Bone turnover markers: a key tool for understanding osteoporosis. Osteoporosis International, 2009, 20, 237-238.	1.3	7
327	Effects of 3 years of lasofoxifene treatment on bone turnover markers in women with postmenopausal osteoporosis. Bone, 2012, 50, 1135-1140.	1.4	7
328	Identification and management of osteoporosis in older adults. Medicine, 2013, 41, 47-52.	0.2	7
329	Effect of denosumab on osteolytic lesion activity after total hip arthroplasty: a single-centre, randomised, double-blind, placebo-controlled, proof of concept trial. Lancet Rheumatology, The, 2021, 3, e195-e203.	2.2	7
330	Morning vs evening dosing of the cathepsin K inhibitor ONO-5334: effects on bone resorption in postmenopausal women in a randomized, phase 1 trial. Osteoporosis International, 2016, 27, 309-318.	1.3	6
331	Variability and Response of Urinary Resorption Markers to Hormone Replacement Therapy. Journal of Bone and Mineral Research, 1999, 14, 471-471.	3.1	5
332	Effect of Pamidronate on Excretion of Pyridinium Crosslinks of Collagen After Total Hip Arthroplasty. Calcified Tissue International, 2003, 73, 326-331.	1.5	5
333	Precision of Periprosthetic Bone Mineral Density Measurements Using Hologic Windows Versus DOS-Based Analysis Software. Journal of Clinical Densitometry, 2006, 9, 363-366.	0.5	5
334	Performance of Quantitative Ultrasound Measurements of Bone for Monitoring Raloxifene Therapy. Journal of Clinical Densitometry, 2010, 13, 441-450.	0.5	5
335	Supine vs Decubitus Lateral Patient Positioning in Vertebral Fracture Assessment. Journal of Clinical Densitometry, 2012, 15, 454-460.	0.5	5
336	Is it time to combine osteoporosis therapies?. Lancet, The, 2013, 382, 5-7.	6.3	5
337	Type I collagen degradation during tissue repair: Comparison of mechanisms following fracture and acute coronary syndromes. Bone, 2014, 69, 1-5.	1.4	5
338	Microarchitecture of bone predicts fractures in older women. Nature Reviews Endocrinology, 2018, 14, 255-256.	4.3	5
339	A History of Pivotal Advances in Clinical Research into Bone and Mineral Diseases. Journal of Bone and Mineral Research, 2018, 33, 5-12.	3.1	5
340	Improving the Hip Fracture Risk Prediction with a Statistical Shape-and-Intensity Model of the Proximal Femur. Annals of Biomedical Engineering, 2022, 50, 211-221.	1.3	5
341	Personalised 3D Assessment of Trochanteric Soft Tissues Improves HIP Fracture Classification Accuracy. Annals of Biomedical Engineering, 2022, 50, 303-313.	1.3	5
342	Randomised Controlled Trial of Nutritional Supplement on Bone Turnover Markers in Indian Premenopausal Women. Nutrients, 2021, 13, 364.	1.7	4

#	Article	IF	Citations
343	Effect of AZD4017, a Selective 11Î²-HSD1 Inhibitor, on Bone Turnover Markers in Postmenopausal Osteopenia. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 2026-2035.	1.8	4
344	Does warfarin increase the risk of osteoporotic fracture?. Nature Clinical Practice Endocrinology and Metabolism, 2006, 2, 484-485.	2.9	3
345	Reply to letter by Gallo and Petrek commenting on interleukinâ€1 receptor antagonist and interleukinâ€6 polymorphisms and postâ€"total hip arthroplasty osteolysis. Arthritis and Rheumatism, 2009, 60, 3856-3857.	6.7	3
346	The central role of the skeleton in chronic diseases. Archives of Biochemistry and Biophysics, 2010, 503, 1.	1.4	3
347	Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism. , 2015, , 489-497.		3
348	Notice of Retraction: Jamal SA, et al. Effect of Nitroglycerin Ointment on Bone Density and Strength in Postmenopausal Women: A Randomized Trial.JAMA. 2011;305(8):800-807.. JAMA - Journal of the American Medical Association, 2016, 315, 418.	3.8	3
349	Response to Letter to the Editor: â€œNormocalcemic Hyperparathyroidism: Study of its Prevalence and Natural Historyâ€. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2689-e2689.	1.8	3
350	Off-treatment bone mineral density changes in postmenopausal women receiving anastrozole for 5 years: 7-year results from the IBIS-II prevention trial. British Journal of Cancer, 2021, 124, 1373-1378.	2.9	3
351	Biochemical markers of bone turnover in osteoporosis. , 2021, , 1545-1588.		3
352	Biochemical Markers of Bone Metabolism. , 2002, , 1543-1571.		3
353	Quantitating Age-Related BMD Textural Variation from DXA Region-Free-Analysis: A Study of Hip Fracture Prediction in Three Cohorts. Journal of Bone and Mineral Research, 2020, 37, 1679-1688.	3.1	3
354	Biochemical Markers of Bone Turnover and Fracture Prediction. The Journal of the British Menopause Society, 2003, 9, 10-16.	1.3	2
355	Risk Assessment and Fracture Discrimination by Ultrasound: The Debate Continues. Journal of Bone and Mineral Research, 2004, 20, 539-540.	3.1	2
356	Measurement of Biochemical Markers of Bone Formation. , 2006, , 529-540.		2
357	Role of Estrogen in the Age-Related Decline in Bone Microstructure. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 519-521.	1.8	2
358	Bone Turnover Markers. , 2018, , 116-127.		2
359	Response Letter to the Editorâ€"Diamond et al, JBMR. Journal of Bone and Mineral Research, 2019, 34, 1185-1186.	3.1	2
360	Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium. European Journal of Endocrinology, 2021, 184, K7-K10.	1.9	2

#	Article	IF	Citations
361	Prevention and management of osteoporosis. Medicine, 2021, 49, 572-577.	0.2	2
362	Measurement of Biochemical Markers of Bone Formation. , 2006, , 529-540.		2
363	Circadian rhythms of bone resorption in normal women and women with postmenopausal osteoporosis using deoxypyridinoline. Bone and Mineral, 1990, 10, S282.	2.0	1
364	Rate of Loss Recalculated. Journal of Bone and Mineral Research, 1999, 14, 1991-1991.	3.1	1
365	Bone turnover markers in clinical practice. , 2002, , 99-114.		1
366	Skeletal Health in Adulthood. Hormone Research in Paediatrics, 2007, 67, 23-27.	0.8	1
367	Defining a â€œReference Populationâ€: No Easy Task. Journal of Bone and Mineral Research, 2009, 24, 1639-1639.	3.1	1
368	Spatio-Temporal Atlas of Bone Mineral Density Ageing. Lecture Notes in Computer Science, 2018, , 720-728.	1.0	1
369	Towards a toolkit for the assessment and monitoring of musculoskeletal ageing. Age and Ageing, 2018, 47, 774-777.	0.7	1
370	Adaptation of Young Men to High Phosphate Intake. , 1998, , 185-190.		1
371	Calcium Requirements During Treatment of Osteoporosis in Women. , 2001, , 307-321.		1
372	Calcium Requirements During Treatment of Osteoporosis in Women. , 2005, , 425-431.		1
373	Biochemical markers in bone disease. , 2015, , 1656-1662.		1
374	Development of a Hypoparathyroid Male Rodent Model for Testing Delayed-Clearance PTH Molecules. Endocrinology, 2022, 163, .	1.4	1
375	Calcium, protein, and phosphorus intakes and bone density. American Journal of Clinical Nutrition, 1994, 60, 455.	2.2	0
376	Optimising the Benefits of Hormone Replacement Therapy for Osteoporosis. The Journal of the British Menopause Society, 1999, 5, 20-23.	1.3	0
377	Seasonal Variation Present and Biologically Significant?. Journal of Bone and Mineral Research, 2003, 19, 170-171.	3.1	0
378	Treating osteoporosis. Women's Health Medicine, 2006, 3, 171-172.	0.0	0

#	Article	IF	Citations
379	Treating osteoporosis. Foundation Years, 2007, 3, 216-218.	0.0	0
380	Bone mineral density and biochemical marker response rates in postmenopausal women after treatment with zoledronic acid. Bone, 2008, 42, S69.	1.4	0
381	Bone turnover markers: An appreciation of the contribution of Dr. P.D. Delmas. Bone, 2008, 43, 649-652.	1.4	0
382	Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density. Obstetrical and Gynecological Survey, 2010, 65, 177-178.	0.2	0
383	Monitoring anti-resorptive treatments for osteoporosis using bone turnover markers. IBMS BoneKEy, 2012, 9, .	0.1	0
384	FP638PERIPHERAL VASCULAR CALCIFICATION AND BONE CHANGES IN ADVANCED CHRONIC KIDNEY DISEASE USING HIGH RESOLUTION PERIPHERAL QUANTITATIVE COMPUTED TOMOGRAPHY (HR-pQCT). Nephrology Dialysis Transplantation, 2015, 30, iii286-iii287.	0.4	0
385	Bone turnover markers: response to comments by Seeman and Nguyen. Osteoporosis International, 2016, 27, 37-37.	1.3	0
386	Authors' Reply. Journal of the American Society of Nephrology: JASN, 2018, 29, 2444-2444.	3.0	0
387	P0885THE RELATIONSHIP BETWEEN BONE REGULATORY MARKERS AND BONE TURNOVER IN RENAL OSTEODYSTROPHY. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
388	Dietary selenium intakes and their association with muscle strength and function in â‰¥ 85 year old adults: the Newcastle 85 + Study. Proceedings of the Nutrition Society, 2020, 79, .	0.4	0
389	The prevalence and natural history of normocalcaemic hypoparathyroidism in a United Kingdom referral population. Clinical Endocrinology, 2020, 93, 119-126.	1.2	0
390	Selenium supplementation to improve bone health in postmenopausal women: the SeMS three-arm RCT. Efficacy and Mechanism Evaluation, 2021, 8, 1-38.	0.9	0
391	In Reply to â€œRisks of Hip and Nonvertebral Fractures in Patients With CKDâ€• American Journal of Kidney Diseases, 2021, 77, 546-547.	2.1	0
392	Development of the Bone Phenotype and <scp>microRNA</scp> Profile in Adults With Lowâ€Density Lipoprotein Receptorâ€Related Protein 5â€“High Bone Mass (<scp>LRP5â€HBM)</scp> Disease. JBMR Plus, 2021, 5, e10534.	1.3	0
393	A Placebo Controlled Randomized Trial of Chromium Picolinate Supplementation on Indices of Bone and Calcium Metabolism in Healthy Women. , 2004, , 141-152.		0
394	Pathogenesis of Transplantation Bone Disease: A Unifying Hypothesis. , 2005, , 209-217.		0
395	Bone Growth in Childhood and Adolescence: The Interpretation of Dietary Supplementation Trials. , 1998, , 50-55.		0